BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mertens IL, Van Gaal LF. Promising New Approaches to the Management of Obesity: . Drugs 2000;60:1-9. [DOI: 10.2165/00003495-200060010-00001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Van Gaal L, Mertens I, Ballaux D, Verkade HJ. Modern, new pharmacotherapy for obesity. A gastrointestinal approach. Best Pract Res Clin Gastroenterol 2004;18:1049-72. [PMID: 15561638 DOI: 10.1016/j.bpg.2004.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
2 Appolinario JC, Bueno JR, Coutinho W. Psychotropic Drugs in the Treatment of Obesity: What Promise? CNS Drugs 2004;18:629-51. [DOI: 10.2165/00023210-200418100-00002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
3 Young R. TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential. CNS Drug Rev 2007;13:405-22. [PMID: 18078426 DOI: 10.1111/j.1527-3458.2007.00022.x] [Reference Citation Analysis]
4 DeWald T, Khaodhiar L, Donahue MP, Blackburn G. Pharmacological and surgical treatments for obesity. Am Heart J 2006;151:604-24. [PMID: 16504622 DOI: 10.1016/j.ahj.2005.03.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hastings JA, Morris MJ, Lambert G, Lambert E, Esler M. NPY and NPY Y1 receptor effects on noradrenaline overflow from the rat brain in vitro. Regul Pept 2004;120:107-12. [PMID: 15177927 DOI: 10.1016/j.regpep.2004.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
6 Bickel M, Gossel M, Geisen K, Jaehne G, Lang HJ, Rosenburg R, Sandow J. Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int J Obes 2004;28:211-21. [DOI: 10.1038/sj.ijo.0802540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Young R, Rothman RB, Rangisetty JB, Partilla JS, Dukat M, Glennon RA. TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of “snacks” in mice. Pharmacology Biochemistry and Behavior 2006;84:74-83. [DOI: 10.1016/j.pbb.2006.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Winter HD, Breslin H, Miskowski T, Kavash R, Somers M. Inhibitor-based validation of a homology model of the active-site of tripeptidyl peptidase II. Journal of Molecular Graphics and Modelling 2005;23:409-18. [DOI: 10.1016/j.jmgm.2004.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Spigset O, Hägg S. Therapeutic approaches to bulimia nervosa. Expert Opinion on Therapeutic Patents 2005;11:463-77. [DOI: 10.1517/13543776.11.3.463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]